Indaptus Therapeutics, Inc. INDP PHARMA
Company Overview
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -78.08% |
| 6 Months: | -1.07% |
| 3 Months: | -11.90% |
| 1 Month: | +56.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- Death Cross9d ago
- RSI (14)64.79 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 78.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INDP Indaptus Therapeutics, Inc. PHARMA | 1.85 | -0.52 | $246.50M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | -2.90M | -1.55M | -613.98K | -528.64K | -3.37M | -3.40M | -3.87M | -3.55M | -4.46M | -3.50M | -4.25M | -3.94M | -4.11M | -3.14M | -4.57M | -4.46M | -2.65M | -2.16M |
| Net Income | -558.58K | -712.62K | -1.54M | -612.42K | -515.48K | -3.37M | -3.37M | -3.84M | -3.47M | -4.25M | -3.25M | -3.92M | -3.81M | -4.02M | -3.07M | -4.53M | -5.23M | -2.98M | -2.54M |
| Diluted EPS | - | - | - | - | - | - | - | -0.46 | -0.42 | -0.51 | -0.39 | -0.47 | -0.45 | -13.16 | -9.04 | -9.11 | -9.09 | -2.98 | -0.23 |
| R&D Expense | - | 1.27M | 1.35M | 489.72K | 391.12K | 697.67K | 1.30M | 1.51M | 1.61M | 1.88M | 1.48M | 2.23M | 1.59M | 1.71M | 1.47M | 2.81M | 2.17M | 1.52M | 491.13K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -3.60M | -7.73M | -14.91M | -16.38M | -15.37M | -19.83M |
| Net Income | -3.58M | -7.71M | -14.32M | -15.42M | -15.02M | -20.85M |
| Diluted EPS | - | - | -1.73 | -1.83 | -44.96 | -21.58 |
| R&D Expense | 2.66M | 2.52M | 6.32M | 7.62M | 7.25M | 9.34M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.78M | 40.58M | 28.06M | 14.92M | 7.34M | 9.31M |
| Total Equity | 3.21M | -237.70K | 35.90M | 24.63M | 12.08M | 3.94M | 3.15M |
| Cash & Equivalents | - | 1.64M | 39.13M | 9.63M | 13.36M | 5.79M | 8.51M |
| Total Liabilities | - | 2.02M | 4.68M | 3.43M | 2.85M | 3.39M | - |
| Current Liabilities | - | 2.02M | 4.60M | 3.43M | 2.77M | 3.39M | 6.16M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.32M | -11.29M | -13.08M | -13.41M | -12.32M | -14.82M |
| Investing Cash Flow | - | 447.75K | -16.43M | 17.14M | - | - |
| Financing Cash Flow | 1.16M | 48.34M | - | - | 4.75M | 17.54M |
| Capital Expenditure | - | -3.85K | - | - | - | - |
| Free Cash Flow | - | -11.29M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 1,507.8% | -21.5% | -58.2% | -127.7% | -380.8% | -661.5% |
| ROCE % | 1,514.2% | -21.5% | -60.5% | -134.8% | -389.5% | -629.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 0.15% | 206.08K | $731.57K |
| 2 | Geode Capital Management, LLC | 0.04% | 56.47K | $200.47K |
| 3 | Jane Street Group, LLC | 0.04% | 53.81K | $191.03K |
| 4 | Vanguard Capital Management LLC | 0.03% | 33.65K | $119.46K |
| 5 | Vanguard Fiduciary Trust Co | 0.01% | 13.97K | $49.58K |
| 6 | Morgan Stanley | 0.01% | 8.94K | $31.72K |
| 7 | Millennium Management Llc | 0.01% | 11.59K | $41.13K |
| 8 | CWM, LLC | - | 2 | $7 |
| 9 | SBI Securities Co., Ltd. | - | 17 | $60 |
| 10 | UBS Group AG | - | 478 | $1.70K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INDP
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNMHoyVzI0SXNuOW5NZUZnNnNFcmdoNTJWUGVyYk9TTTBqZmRaSERkM28yY2JKNE1McnpFb1ZrcVptNzN3Tzk2dVFTMDB4c19zdzU4aG9Ya1pLN1A0NzBhME9hOGlycFRwQkcyYWw0M2xyRURHMWdreVltdmR6Qlk4OEs4cVd0RFcxSVlSWV…
Indaptus Therapeutics (INDP) updates $100M stock sale plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPdE5KREVRd0JmQ2tHZXdvZFpfaXlWYmtiVHdfUGZBMW1xbTJtdVo4elFNNEo1bHMxcHQ2d25odHQxaTZibDYwLXNkZW40Z2h2MHBXdk02NUpUeGpsZlJmWnZldjdnLWdQMFZvWFo5NV93dFJEaHZHYnp5Ml9tZERVXzBhQmlNTEV6T0lBRT…
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOWF9JRk45aVNKLWhXMFdWU3hTM3R4UTlQUmQyUHd6UndBVlZaWTNtNUh5MDhxM2RLQU9pc3d0eVV6cDBWR3RQZ0FuNlVfelFsWDdyZzB1N2RMS2ZnLWwwNEhYbkVGdUJGRHN0SzFDRUJ0dU5jWnB3VzZUUllKR0ZtRlhHaUtXcmlpMWNwc1…
Why Did INDP Stock Gain 12% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOeDFJT2t5R2Jxc0hPR1h6OEJnMmI0N0g0SkV2YUF6Z2k3eFh6TDJocDFQd1ZoTGhGZ3Q2aC1DSmt1M25OVmJ0ZnV1MFN6alRRUVcydDRGdWYzZ0VJX2xCQzd5YW0zODJmNXVNUEFTY0ZwYjhLQVBhb1ZTaEtOb01SWGtmRkdfWklTV1NNd3…
Insider Traders Lose US$34k As Indaptus Therapeutics Drops - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNc28wR0lWTklNTVgwQzVmVmNrOGRtb1k0YzU1djFRSnlzbVFSSDhyeFFCaWdzaW1ycnVQSVg5RU9GX0dSMXRwd2NmaGRYYTRUbDhiRTJzajV1a1ZZM01KZjVxRC1kcnkzb2xaaWtiM21TTDhYbFRpY3QtWHR0eEQweC1haUtqV2hsZXR5NS…
Indaptus sets up $100M at-the-market stock program - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxORFNYWmY2TmVPYWVXMjBuVEM4THJNNk1ScHc3V29fVlNVTjVFWGRiQWRvWTlBUjZBU0JtbkxCSEhKY2Y5WUUyVTVJeTJiRks2bkxFV1BUQVBrRi11akxqZTZyZ0JWN3BmRWgzWlVXNnJRZTdaZ3lYbzRhb3V2ODliU0ZRVUNtMV9Fd3NqcX…
INDP — Frequently Asked Questions
What is the current share price of Indaptus Therapeutics, Inc. (INDP)?
As of 2026-09-19 21:16 PDT, Indaptus Therapeutics, Inc. (INDP) trades at $1.85 on NasdaqCM. Its 52-week range is $0.94 to $8.44.
What is the market capitalisation of INDP?
Indaptus Therapeutics, Inc. (INDP) has a market capitalisation of $246.50M on NasdaqCM.
What is the P/E ratio of INDP?
INDP trades at a trailing price-to-earnings (P/E) ratio of -0.52. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 41.76.
Is INDP a good stock to buy?
This page provides a data-driven analysis of Indaptus Therapeutics, Inc. (INDP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.